| Prev Close | 95.85 |
| Open | 95.90 |
| Day Low/High | 93.25 / 97.41 |
| 52 Wk Low/High | 28.35 / 97.14 |
| Volume | 972.84K |
| Avg Volume | 1.68M |
| Exchange | NASDAQ |
| Shares Outstanding | 36.97M |
| Market Cap | 3.49B |
| EPS | -8.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
U.S. Food And Drug Administration Approves Puma's NERLYNX™ (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
Puma Biotechnology, Inc. (Nasdaq: PBYI) today announced that the U.
Puma Biotechnology Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with...
PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. to Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.
The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.
The Klein Law Firm Announces A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.
PBYI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.
Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round
Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.
Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)
It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.
'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio
This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
Puma Biotechnology Announces Positive PB272 Phase II Data From TBCRC 022 Trial In Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases At The 2017 ASCO Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of...
PBYI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.
Puma Biotechnology To Present At The Jefferies 2017 Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.
Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential
A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring
Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday.
Puma Biotechnology Receives FDA Advisory Committee Support For Neratinib
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that the U.
This Market is Now Overbought; Waiting for Another Pullback
Despite the good action in the indices, I'm not putting much money to work.
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote
The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.
Puma Biotechnology Announces Posting Of FDA Oncologic Drugs Advisory Committee Briefing Documents For Neratinib Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the U.
Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2017 ASCO Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...
Puma Biotechnology Reports First Quarter 2017 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017.
Puma Biotechnology To Present At Bank Of America Merrill Lynch 2017 Health Care Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
